Athira Pharma (ATHA) Management Meeting Takeaways - Goldman Sachs

Goldman Sachs analyst Graig Suvannavejh reiterated a Neutral rating and $50.00 price target on Athira Pharma (NASDAQ: ATHA) after hosting investor meetings to discuss the evolving competitive landscape in AD, especially in light of the upcoming 15th International Conference of Alzheimer’s and Parkinson’s Diseases (AD/PD), currently taking place.

The analyst stated "With key Phase 2 readouts for ATH-1017 not expected until 2022, 2021 marks a year of execution for the company. Main ATH-1017-related objectives involve (1) clinical trial site activation and patient enrollment in the smaller Phase 2 ACT-AD study (N=75) and in the larger Phase 2 LIFT-AD study (N=300), which depending on the strength of the data, could potentially be considered to be a registrational study to support FDA approval, and also (2) progress towards an investigational new drug application (IND) for ATH-1017 in Parkinson’s disease dementia (PDD), a next potential indication. Beyond ATH-1017, ATHA is also advancing its earlier stage assets, which are being developed as potential treatments for neuropsychiatric disorders, with a first IND targeted for YE21." He went on to state "ATHA represents a higher risk, but higher reward opportunity. That said, we came away encouraged by positive receptivity to ATHA, whose meetings involved investors both new to and long-standing with the company."

For an analyst ratings summary and ratings history on Athira Pharma click here. For more ratings news on Athira Pharma click here.

Shares of Athira Pharma closed at $20.22 yesterday.

You May Also Be Interested In

• Boston Scientific (BSX) PT Raised to $83 at Stifel
• Ameriprise Financial (AMP) PT Raised to $445 at Morgan Stanley
• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'